论文部分内容阅读
目的 探讨III期非小细胞肺癌 (NSCLC)新辅助化疗的可行性及毒性反应并评价其有效性。方法 对 2 0 0 1年 1月～2 0 0 2年 10月 89例病例进行回顾性研究 ,其中新辅助化疗组 37例 ,对照组 5 2例。试验组给予术前NVB +DDP化疗两周期 ,对照组则直接行手术治疗。结果 新辅助化疗组有效率为 75 .6 7% (2 8/ 37) ,病期下调率为 4 3.2 4 % (16 / 37) ,手术切除率为97.2 2 % ,对照组切除率为 92 .30 % ,两组手术失血量 ,手术并发症和手术死亡率均无显著性差异。结论 术前新辅助化疗安全、有效 ,能降低III期非小细胞肺癌的病期 ,有助于提高手术切除率。
Objective To investigate the feasibility and toxicity of neoadjuvant chemotherapy for stage III non-small cell lung cancer (NSCLC) and evaluate its efficacy. Methods A retrospective study was performed on 89 cases from January 2001 to October 2002, including 37 cases of neoadjuvant chemotherapy group and 52 cases of control group. The experimental group was given preoperative NVB + DDP two cycles of chemotherapy, while the control group was treated directly with surgery. Results The effective rate of neoadjuvant chemotherapy group was 75.67% (28/37). The down - regulation rate was 42.24% (16/37) in the neoadjuvant chemotherapy group and 97.22% in the neoadjuvant chemotherapy group. The resection rate in the control group was 92%. 30%. There was no significant difference between the two groups in the amount of blood loss, operative complications and operative mortality. Conclusions Neoadjuvant chemotherapy before operation is safe and effective, which can reduce the stage of stage III non-small cell lung cancer and improve the resection rate.